|By PR Newswire||
|April 1, 2014 08:00 PM EDT||
DUBLIN, April 2, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/pttfr4/cancer_gene) has announced the addition of the "Cancer Gene Therapy Market Analysis" report to their offering.
The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer.
The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.
A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines.
Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer.
Key Topics Covered:
1. Introduction to Gene Therapy
2. Global Gene Therapy Market
3. Significance of Cancer Therapeutics in Gene Therapy
4. Current Applications of Gene Therapy to Cancer Treatment
5. Cancer Gene Therapy Market Dynamics
6. Regulatory Scenario for Gene Therapy Market
7. Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications
8. Marketed Cancer Gene Therapy Drugs
9. Suspended & Discontinued Cancer Gene Therapy Drug Pipeline
10. Competitive Landscape
- Cell Genesys
- Epeius Biotechnologies
- Introgen Therapeutics
- Shenzhen SiBiono GeneTech
- ZIOPHARM Oncology
For more information visit http://www.researchandmarkets.com/research/pttfr4/cancer_gene
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Jul. 6, 2015 11:00 PM EDT Reads: 1,878
Jul. 6, 2015 09:00 PM EDT Reads: 1,126
Jul. 6, 2015 07:45 PM EDT Reads: 1,575
Jul. 6, 2015 07:45 PM EDT Reads: 1,857
Jul. 6, 2015 07:00 PM EDT Reads: 1,066
Jul. 6, 2015 06:15 PM EDT Reads: 1,943
Jul. 6, 2015 05:30 PM EDT Reads: 1,090
Jul. 6, 2015 05:00 PM EDT Reads: 2,151
Jul. 6, 2015 05:00 PM EDT Reads: 1,946
Jul. 6, 2015 04:30 PM EDT Reads: 635
Jul. 6, 2015 04:15 PM EDT Reads: 1,556
Jul. 6, 2015 03:45 PM EDT Reads: 1,753
Jul. 6, 2015 03:00 PM EDT Reads: 1,797
Jul. 6, 2015 03:00 PM EDT Reads: 3,040
"The idea of polyglot persistence is you have to apply the right database for the job - you always have to have many different databases in play. We offer that whole system as a service," explained Raj Singh, Developer Advocate for IBM Cloud Data Services, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Jul. 6, 2015 03:00 PM EDT Reads: 889